Abstract:
Objective To investigate the predictive value of serum circular RNA (circRNA) CDYL and circRNA ACAP2 expression levels for major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI).
Methods A total of 98 AMI patients were enrolled into the observation group, and divided into MACE group (n=45) and no-MACE group (n=53) based on whether they experienced MACE. Another 98 healthy individuals who underwent physical examination during the same period were selected as the control group. The expression levels of serum circRNA CDYL and circRNA ACAP2 were compared among groups. Multivariate logistic regression analysis was used to identify factors influencing the occurrence of MACE in AMI patients. Receiver operating characteristic (ROC) curve analysis was conducted to evaluate the predictive value of serum circRNA CDYL and circRNA ACAP2 levels for MACE in AMI patients.
Results The serum circRNA CDYL level in the observation group was significantly lower than that in the control group, while the circRNA ACAP2 level was significantly higher (P < 0.05). The circRNA CDYL level in the MACE group was significantly lower, and the circRNA ACAP2 level was significantly higher than that in the no-MACE group (P < 0.05). Heart rate and circRNA ACAP2 were identified as independent risk factors for MACE in AMI patients, whereas circRNA CDYL served as independent protective factor (P < 0.05). The area under the ROC curve (AUC) for predicting MACE in AMI patients using serum circRNA CDYL, circRNA ACAP2 and their combination were 0.814, 0.821 and 0.921, respectively. The sensitivity and specificity of combined prediction using serum circRNA CDYL and circRNA ACAP2 were 91.11% and 79.25%, respectively. The combined prediction efficacy of serum circRNA CDYL and circRNA ACAP2 was superior to their individual prediction (Zcombined-circRNA CDYL = 1.975, Zcombined-circRNA ACAP2 = 2.064, P=0.048, 0.039).
Conclusion Serum circRNA CDYL level is down-regulated and circRNA ACAP2 level is up-regulated in AMI patients, and circRNA ACAP2 is an independent risk factor for MACE, while circRNA CDYL is a independent protective factor. The combined value of circRNA CDYL and circRNA ACAP2 in predicting the occurrence of MACE is higher.